Limits...
Effect of trandolapril on regression of retinopathy in hypertensive patients with type 2 diabetes: a prespecified analysis of the benedict trial.

Ruggenenti P, Iliev I, Filipponi M, Tadini S, Perna A, Ganeva M, Ene-Iordache B, Cravedi P, Trevisan R, Bossi A, Remuzzi G - J Ophthalmol (2010)

Bottom Line: Methods.Results.Conclusions.

View Article: PubMed Central - PubMed

Affiliation: Clinical Research Center for Rare Diseases 'Aldo & Cele Daccò', Mario Negri Institute for Pharmacological Research, Negri Bergamo Laboratories, Via Gavazzeni, 11, 24125 Bergamo, Italy.

ABSTRACT
Background. The effect of angiotensin converting enzyme inhibitors (ACEi) on regression of retinopathy in type 2 diabetics is still ill defined. Methods. We compared the incidence of retinopathy regression in 90 hypertensive type 2 diabetics randomized to at least 3-year blinded ACEi with trandolapril (2 mg/day) or non-ACEi therapy who had preproliferative or proliferative retinopathy at baseline. Results. Over a median (interquartile range) follow-up period of 35.8 (12.4-60.7) months, retinopathy regressed in 27 patients (30.0%). Regression occurred in 18 of 42 patients (42.9%) on ACEi and in 9 of 48 (18.8%) on non-ACEi therapy (adjusted for predefined baseline covariates HR (95% CI): 2.75 (1.18-6.42), P = .0193). Concomitant treatment with or without Non-Dihydropyridine Calcium Channel Blockers (ndCCBs) did not appreciably affect the incidence of retinopathy regression. Conclusions. Unlike ndCCB, ACEi therapy may have an additional effect to that of intensified BP and metabolic control in promoting regression of diabetic retinopathy.

No MeSH data available.


Related in: MedlinePlus

Study flow chart.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2901608&req=5

fig1: Study flow chart.

Mentions: The analysis was primarily aimed at evaluating the rate of regression of diabetic retinopathy in patients with retinal involvement at study entry considered as a whole and, then, according to their original randomization to RAS-inhibitor or non-RAS inhibitor therapy (Figure 1). Secondarily, the study compared the effect of RAS and non-RAS inhibitor therapy on newly onset retinopathy in those without evidence of retinal involvement at inclusion. Finally, for explorative purposes only, patients were considered according to their randomization to one of the four original treatment arms.


Effect of trandolapril on regression of retinopathy in hypertensive patients with type 2 diabetes: a prespecified analysis of the benedict trial.

Ruggenenti P, Iliev I, Filipponi M, Tadini S, Perna A, Ganeva M, Ene-Iordache B, Cravedi P, Trevisan R, Bossi A, Remuzzi G - J Ophthalmol (2010)

Study flow chart.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2901608&req=5

fig1: Study flow chart.
Mentions: The analysis was primarily aimed at evaluating the rate of regression of diabetic retinopathy in patients with retinal involvement at study entry considered as a whole and, then, according to their original randomization to RAS-inhibitor or non-RAS inhibitor therapy (Figure 1). Secondarily, the study compared the effect of RAS and non-RAS inhibitor therapy on newly onset retinopathy in those without evidence of retinal involvement at inclusion. Finally, for explorative purposes only, patients were considered according to their randomization to one of the four original treatment arms.

Bottom Line: Methods.Results.Conclusions.

View Article: PubMed Central - PubMed

Affiliation: Clinical Research Center for Rare Diseases 'Aldo & Cele Daccò', Mario Negri Institute for Pharmacological Research, Negri Bergamo Laboratories, Via Gavazzeni, 11, 24125 Bergamo, Italy.

ABSTRACT
Background. The effect of angiotensin converting enzyme inhibitors (ACEi) on regression of retinopathy in type 2 diabetics is still ill defined. Methods. We compared the incidence of retinopathy regression in 90 hypertensive type 2 diabetics randomized to at least 3-year blinded ACEi with trandolapril (2 mg/day) or non-ACEi therapy who had preproliferative or proliferative retinopathy at baseline. Results. Over a median (interquartile range) follow-up period of 35.8 (12.4-60.7) months, retinopathy regressed in 27 patients (30.0%). Regression occurred in 18 of 42 patients (42.9%) on ACEi and in 9 of 48 (18.8%) on non-ACEi therapy (adjusted for predefined baseline covariates HR (95% CI): 2.75 (1.18-6.42), P = .0193). Concomitant treatment with or without Non-Dihydropyridine Calcium Channel Blockers (ndCCBs) did not appreciably affect the incidence of retinopathy regression. Conclusions. Unlike ndCCB, ACEi therapy may have an additional effect to that of intensified BP and metabolic control in promoting regression of diabetic retinopathy.

No MeSH data available.


Related in: MedlinePlus